Pennington, NJ, United States of America

William L Parker

This inventor holds 11 USPTO granted patents. Top assignees: E. R. Squibb Sons, Inc., Bristol-Myers Squibb Compnay. Active years: 1976-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: William L Parker. Retrieved from https://idiyas.com/inventor/william-l-parker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 100.0

Average Co-Inventor Count = 2.7

ph-index = 4

Forward Citations = 66(Granted Patents)

Company Filing History:

10 out of 1,624

E. R. Squibb Sons, Inc.

patents

1 out of 3,745

Bristol-Myers Squibb Compnay

patents

Years Active: 1976-2002

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6413969 - Gatifloxacin pentahydrate (2002-07-02),

2. 4842857 - Glyphomicins A and B (1989-06-27),

3. 4775670 - 2-oxo-1-azetidinesulfonic acid salts (1988-10-04),

4. 4745202 - Aerocyanidin-antibiotic (1988-05-17),

5. 4686299 - Aerocavin antibiotics (1987-08-11),

6. 4529698 - Process for preparing a 2-oxo-1-azetidinesulfonic acid salt (1985-07-16),

7. 4503218 - Antibiotic cepacin (1985-03-05),

8. 4362814 - Process for preparing 1-carba-2-penem-3-carboxylic acid (1982-12-07),

9. 4321326 - Process for preparing antibiotics (1982-03-23),

10. 4091092 - Polymyxin F and process of producing polymyxin F (1978-05-23),

11. 3941762 - O-acyl derivatives of antibiotic EM-49 (1976-03-02),

Title: The Innovative Contributions of William L. Parker

Introduction

William L. Parker is a notable inventor based in Pennington, NJ (US), recognized for his significant contributions to the field of microbiology and antibiotic development. With a total of 11 patents to his name, Parker has made a lasting impact on the pharmaceutical industry.

Latest Patents

Among his latest patents is the development of Gatifloxacin pentahydrate, which showcases his expertise in creating novel antibiotic substances. His work on Glyphomicins A and B involves the cultivation of a strain of the microorganism Micromonospora sp. A.T.C.C. No. 53481, yielding the innovative antibiotic glyphomicin, a mixture of glyphomicin A and glyphomicin B.

Career Highlights

Parker has had a distinguished career, working with prominent companies such as E.R. Squibb & Sons, Inc. and Bristol-Myers Squibb Company. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical sector.

Collaborations

Throughout his career, Parker has collaborated with esteemed colleagues, including Richard B. Sykes and Christopher M. Cimarusti. These partnerships have further enhanced his research and innovation efforts.

Conclusion

William L. Parker's contributions to antibiotic development and microbiology exemplify the spirit of innovation in the pharmaceutical industry. His work continues to influence the field and inspire future advancements.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]